Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MergersPR NewswireFiled 3 days ago

Viatris (VTRS) Completes Acquisition of Pacira BioSciences

Open the sourceReported by PR Newswire, prnewswire.com, 17 November 2026, by PR Newswire

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Viatris completed its acquisition of Pacira BioSciences, adding the non-opioid pain-management specialist to its portfolio. The deal, first announced earlier, closed on Nov. 17, 2026, with Viatris (Nasdaq: VTRS) absorbing Pacira (Nasdaq: PCRX). The move expands Viatris's offerings in non-opioid pain treatment, a segment where Pacira is a leader. Investors will watch how quickly Viatris integrates Pacira's products and whether the combined portfolio lifts growth.

Muhabbit's AI wrote this summary in its own words from PR Newswire's report. It can get details wrong, so check the source.

Named in this story

Viatris (VTRS), Viatris Inc., Pacira BioSciences, Inc.

A linked name opens that asset's sentiment page.